FGF23 is elevated in multiple myeloma and increases heparanase expression by tumor cells

Attaya Suvannasankha, Douglas R. Tompkins, Daniel F. Edwards, Katarina V. Petyaykina, Colin D. Crean, Pierrick G. Fournier, Jamie M. Parker, George Sandusky, Shoji Ichikawa, Erik Imel, John Chirgwin

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Multiply myeloma (MM) grows in and destroys bone, where osteocytes secrete FGF23, a hormone which affects phosphate homeostasis and aging. We report that multiple myeloma (MM) cells express receptors for and respond to FGF23. FGF23 increased mRNA for EGR1 and its target heparanase, a pro-osteolytic factor in MM. FGF23 signals through a complex of klotho and a classical FGF receptor (FGFR); both were expressed by MM cell lines and patient samples. Bone marrow plasma cells from 42 MM patients stained positively for klotho, while plasma cells from 8 patients with monoclonal gammopathy of undetermined significance (MGUS) and 6 controls were negative. Intact, active FGF23 was increased 2.9X in sera of MM patients compared to controls. FGF23 was not expressed by human MM cells, but co-culture with mouse bone increased its mRNA. The FGFR inhibitor NVP-BGJ398 blocked the heparanase response to FGF23. NVP-BGJ398 did not inhibit 8226 growth in vitro but significantly suppressed growth in bone and induction of the osteoclast regulator RANK ligand, while decreasing heparanase mRNA. The bone microenvironment provides resistance to some anti-tumor drugs but increased the activity of NVP-BGJ398 against 8226 cells. The FGF23/klotho/heparanase signaling axis may offer targets for treatment of MM in bone.

Original languageEnglish
Pages (from-to)19647-19660
Number of pages14
JournalOncotarget
Volume6
Issue number23
StatePublished - 2015

Fingerprint

Multiple Myeloma
Bone and Bones
Fibroblast Growth Factor Receptors
Plasma Cells
Messenger RNA
Neoplasms
Monoclonal Gammopathy of Undetermined Significance
RANK Ligand
Osteocytes
Bone Development
Osteoclasts
Coculture Techniques
Bone Marrow Cells
Homeostasis
Cell Culture Techniques
Phosphates
Hormones
Cell Line
heparanase
Growth

Keywords

  • FGF receptor
  • FGF23
  • Klotho
  • Multiple myeloma
  • Osteocytes

ASJC Scopus subject areas

  • Oncology

Cite this

Suvannasankha, A., Tompkins, D. R., Edwards, D. F., Petyaykina, K. V., Crean, C. D., Fournier, P. G., ... Chirgwin, J. (2015). FGF23 is elevated in multiple myeloma and increases heparanase expression by tumor cells. Oncotarget, 6(23), 19647-19660.

FGF23 is elevated in multiple myeloma and increases heparanase expression by tumor cells. / Suvannasankha, Attaya; Tompkins, Douglas R.; Edwards, Daniel F.; Petyaykina, Katarina V.; Crean, Colin D.; Fournier, Pierrick G.; Parker, Jamie M.; Sandusky, George; Ichikawa, Shoji; Imel, Erik; Chirgwin, John.

In: Oncotarget, Vol. 6, No. 23, 2015, p. 19647-19660.

Research output: Contribution to journalArticle

Suvannasankha, A, Tompkins, DR, Edwards, DF, Petyaykina, KV, Crean, CD, Fournier, PG, Parker, JM, Sandusky, G, Ichikawa, S, Imel, E & Chirgwin, J 2015, 'FGF23 is elevated in multiple myeloma and increases heparanase expression by tumor cells', Oncotarget, vol. 6, no. 23, pp. 19647-19660.
Suvannasankha A, Tompkins DR, Edwards DF, Petyaykina KV, Crean CD, Fournier PG et al. FGF23 is elevated in multiple myeloma and increases heparanase expression by tumor cells. Oncotarget. 2015;6(23):19647-19660.
Suvannasankha, Attaya ; Tompkins, Douglas R. ; Edwards, Daniel F. ; Petyaykina, Katarina V. ; Crean, Colin D. ; Fournier, Pierrick G. ; Parker, Jamie M. ; Sandusky, George ; Ichikawa, Shoji ; Imel, Erik ; Chirgwin, John. / FGF23 is elevated in multiple myeloma and increases heparanase expression by tumor cells. In: Oncotarget. 2015 ; Vol. 6, No. 23. pp. 19647-19660.
@article{bab209e1bb2141c78984545cae5f39b4,
title = "FGF23 is elevated in multiple myeloma and increases heparanase expression by tumor cells",
abstract = "Multiply myeloma (MM) grows in and destroys bone, where osteocytes secrete FGF23, a hormone which affects phosphate homeostasis and aging. We report that multiple myeloma (MM) cells express receptors for and respond to FGF23. FGF23 increased mRNA for EGR1 and its target heparanase, a pro-osteolytic factor in MM. FGF23 signals through a complex of klotho and a classical FGF receptor (FGFR); both were expressed by MM cell lines and patient samples. Bone marrow plasma cells from 42 MM patients stained positively for klotho, while plasma cells from 8 patients with monoclonal gammopathy of undetermined significance (MGUS) and 6 controls were negative. Intact, active FGF23 was increased 2.9X in sera of MM patients compared to controls. FGF23 was not expressed by human MM cells, but co-culture with mouse bone increased its mRNA. The FGFR inhibitor NVP-BGJ398 blocked the heparanase response to FGF23. NVP-BGJ398 did not inhibit 8226 growth in vitro but significantly suppressed growth in bone and induction of the osteoclast regulator RANK ligand, while decreasing heparanase mRNA. The bone microenvironment provides resistance to some anti-tumor drugs but increased the activity of NVP-BGJ398 against 8226 cells. The FGF23/klotho/heparanase signaling axis may offer targets for treatment of MM in bone.",
keywords = "FGF receptor, FGF23, Klotho, Multiple myeloma, Osteocytes",
author = "Attaya Suvannasankha and Tompkins, {Douglas R.} and Edwards, {Daniel F.} and Petyaykina, {Katarina V.} and Crean, {Colin D.} and Fournier, {Pierrick G.} and Parker, {Jamie M.} and George Sandusky and Shoji Ichikawa and Erik Imel and John Chirgwin",
year = "2015",
language = "English",
volume = "6",
pages = "19647--19660",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "23",

}

TY - JOUR

T1 - FGF23 is elevated in multiple myeloma and increases heparanase expression by tumor cells

AU - Suvannasankha, Attaya

AU - Tompkins, Douglas R.

AU - Edwards, Daniel F.

AU - Petyaykina, Katarina V.

AU - Crean, Colin D.

AU - Fournier, Pierrick G.

AU - Parker, Jamie M.

AU - Sandusky, George

AU - Ichikawa, Shoji

AU - Imel, Erik

AU - Chirgwin, John

PY - 2015

Y1 - 2015

N2 - Multiply myeloma (MM) grows in and destroys bone, where osteocytes secrete FGF23, a hormone which affects phosphate homeostasis and aging. We report that multiple myeloma (MM) cells express receptors for and respond to FGF23. FGF23 increased mRNA for EGR1 and its target heparanase, a pro-osteolytic factor in MM. FGF23 signals through a complex of klotho and a classical FGF receptor (FGFR); both were expressed by MM cell lines and patient samples. Bone marrow plasma cells from 42 MM patients stained positively for klotho, while plasma cells from 8 patients with monoclonal gammopathy of undetermined significance (MGUS) and 6 controls were negative. Intact, active FGF23 was increased 2.9X in sera of MM patients compared to controls. FGF23 was not expressed by human MM cells, but co-culture with mouse bone increased its mRNA. The FGFR inhibitor NVP-BGJ398 blocked the heparanase response to FGF23. NVP-BGJ398 did not inhibit 8226 growth in vitro but significantly suppressed growth in bone and induction of the osteoclast regulator RANK ligand, while decreasing heparanase mRNA. The bone microenvironment provides resistance to some anti-tumor drugs but increased the activity of NVP-BGJ398 against 8226 cells. The FGF23/klotho/heparanase signaling axis may offer targets for treatment of MM in bone.

AB - Multiply myeloma (MM) grows in and destroys bone, where osteocytes secrete FGF23, a hormone which affects phosphate homeostasis and aging. We report that multiple myeloma (MM) cells express receptors for and respond to FGF23. FGF23 increased mRNA for EGR1 and its target heparanase, a pro-osteolytic factor in MM. FGF23 signals through a complex of klotho and a classical FGF receptor (FGFR); both were expressed by MM cell lines and patient samples. Bone marrow plasma cells from 42 MM patients stained positively for klotho, while plasma cells from 8 patients with monoclonal gammopathy of undetermined significance (MGUS) and 6 controls were negative. Intact, active FGF23 was increased 2.9X in sera of MM patients compared to controls. FGF23 was not expressed by human MM cells, but co-culture with mouse bone increased its mRNA. The FGFR inhibitor NVP-BGJ398 blocked the heparanase response to FGF23. NVP-BGJ398 did not inhibit 8226 growth in vitro but significantly suppressed growth in bone and induction of the osteoclast regulator RANK ligand, while decreasing heparanase mRNA. The bone microenvironment provides resistance to some anti-tumor drugs but increased the activity of NVP-BGJ398 against 8226 cells. The FGF23/klotho/heparanase signaling axis may offer targets for treatment of MM in bone.

KW - FGF receptor

KW - FGF23

KW - Klotho

KW - Multiple myeloma

KW - Osteocytes

UR - http://www.scopus.com/inward/record.url?scp=84939230403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939230403&partnerID=8YFLogxK

M3 - Article

C2 - 25944690

AN - SCOPUS:84939230403

VL - 6

SP - 19647

EP - 19660

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 23

ER -